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ABSTRACT 
 
REGULATION OF JAK1 AND JAK2 SYNTHESIS THROUGH NON-CLASSICAL 
PROGESTIN RECEPTORS 
 
SEPTEMBER 2015 
 
HILLARY L. ADAMS 
 
B.S. UNIVERSITY OF MASSACHUSETTS AMHERST 
 
M.S. UNIVERSITY OF MASSACHUSETTS AMHERST 
 
Directed by:  Professor Sandra L. Petersen 
 
 
The anteroventral periventricular (AVPV) nucleus of the hypothalamus integrates 
estradiol (E2) and progesterone (P4) feedback signals from the ovaries to stimulate 
gonadotropin releasing hormone (GnRH) neurons and trigger an ovulatory surge in 
luteinizing hormone (LH).  E2 maintains the daily cyclic LH surge and P4 quickly 
amplifies the surge and limits it to one day.  P4 amplification of the surge and rapid 
signaling in the AVPV may occur through its non-classical progestin receptors.  Previous 
in vitro studies using a microarray analysis with N42 mouse embryonic hypothalamic 
neurons suggest that progesterone membrane component 1 (Pgrmc1) regulates genes 
linked to the janus kinase (Jak)/signal transducer and activator of transcription (Stat) 
signaling pathway.  I hypothesized that P4 alters Jak/Stats through Pgrmc1 regulation of 
one or more Jak or Stat molecules and then performed a set of in vitro and in vivo studies 
to test this.  I transfected N42 cells with either scramble or Pgrmc1 siRNA followed by 
treatment with either ethanol vehicle control or 10 nM P4 and measured Jak1, Jak2, Stat3, 
Stat5a, Stat5b, and Stat6 mRNA levels via quantitative polymerase chain reaction 
iv 
 
(QPCR).  Jak1 and Jak2 mRNAs increased with P4 treatments, and this upregulation 
required Pgrmc1.  Silencing Pgrmc1 in the cells also produced an increase in Jak1 and 
Jak2 mRNA, suggesting that Pgrmc1 constitutively suppressed jak1 and jak2 in the 
absence of P4.  None of the Stats were significantly regulated by P4 or Pgrmc1 silencing.  
To determine how Pgrmc1 regulates Jak/Stat in vivo, I took AVPV microdissections from 
Pgrmc1 and Pgrmc2 double conditional knockout (DCKO) mice and looked at gene 
expression of jak/stat.  Transcript levels of Jak2, but not Jak1, were severely 
downregulated in the DCKO animals and Stat mRNAs were not significantly changed.  
Discrepancies from in vitro and in vivo data prompted me to analyze the role of the class 
II progestin and adipoQ (Paqr) receptors in Jak/Stat signaling.  P4 treatments and siRNA 
experiments in N42 cells showed that Paqr8, but not Paqr7, was required for P4 
upregulation of Jak1 and Jak2 mRNAs.  Overall, these findings show that Pgrmc1 
regulates Jak1 and Jak2 synthesis in a P4-dependent and -independent manner that 
requires interaction with Paqr8.   
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CHAPTER 1 
INTRODUCTION 
 
1.1 Progesterone and its neuroendocrine role in ovulation 
Inducing ovulation involves intricate signaling mechanisms regulated by the brain and 
the cycling of progesterone (P4) and estradiol (E2) in the hypothalamic pituitary gonadal 
(HPG) axis.  Gonadotropin-releasing hormone (GnRH) secreted from the hypothalamus 
triggers the pituitary gland to release luteinizing hormone (LH) and follicle stimulating 
hormone (FSH) (Clark and Cummins, 1985).  LH and FSH bind receptors in the ovaries, 
advancing their production of E2 and P4.  E2 positive feedback to the hypothalamus is 
necessary to stimulate GnRH neurons and initiate an LH surge, but the surge is not 
maximal without P4 (Christian et al., 2005; DePaolo and Barraclough, 1979).   
 
1.2 The anteroventral periventricular (AVPV) nucleus  
It has long been understood that the anteroventral periventricular nucleus (AVPV) of the 
preoptic area (POA) is the control center in the hypothalamus that integrates ovarian E2-
positive feedback and neural P4 signaling to directly stimulate GnRH neurons and 
generate an LH surge for ovulation (Petersen et al., 2003).  Estrogen receptors (ERs) 
within the POA are most densely populated in the AVPV and estrogen deprivation to the 
AVPV prevents LH release (Ottem et al., 2004; Petersen et al., 1989).  E2 also induces 
expression of nuclear progesterone receptor (Pgr) in the AVPV, the activation of which is 
required for the LH surge (Simerly et al., 1996; Chappell and Levine, 2000).  While P4 
signaling in the AVPV is necessary for the LH surge, directly stimulating GnRH neurons 
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with P4 inhibits LH release (Richter et al., 2001), confirming the dominant role of the 
AVPV in GnRH surge release.  
 
Although P4 activation of Pgr in the AVPV may be required for gonadotropin release, 
other studies have shown that Pgr stimulation in this region may be ligand-independent 
(Mani et al., 1996) and P4 can also signal in the absence of Pgr (Frye et al., 2006; Sleiter 
et al., 2009).  Moreover, Pgr-mediated genomic effects do not fully explain the rapid 
signaling that P4 wields on the system (Ke and Ramirez, 1987).  Therefore it is quite 
possible that rapid P4 signaling in the AVPV involves other P4 mediators. 
 
1.3 Non-classical P4 receptors 
Two different groups of non-classical P4 receptors exist: the membrane P4 receptors 
(mPR) that belong to the class II progestin and adipoQ (PAQR) family comprising of 
mPRα (Paqr7), mPRβ (Paqr8), mPRγ (Paqr5), mPRδ (Paqr6), mPRε (Paqr9), and the 
membrane-associated P4 receptor (MAPR) family comprised of P4 receptor membrane 
component 1 (Pgrmc1), Pgrmc2, and neudesin (Thomas and Pang, 2012).  All of the 
mPRs and Pgrmc1 display high binding affinity for P4 (Peluso et al., 2006).  Several 
studies in non-neural tissue have verified the localization of mPRs to plasma membranes 
where they mediate P4 signaling through G protein activation (Zhu et al., 2003; Pang and 
Thomas, 2011) and current findings suggest that Paqr7 and Pgrmc1 interact to regulate P4 
effects (Thomas et al., 2014; Sueldo et al., 2015) 
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Recent studies have mapped pgrmc1, pgrmc2, paqr7 and paqr8 family members to 
several regions in the brain, including but not limited to the hypothalamus, thalamus, 
hippocampus, and cortex (Zuloaga et al., 2012; Intlkeofer and Petersen, 2011).  However, 
in situ hybridization experiments in the adult rat forebrain revealed that pgrmc1 and 
pgrmc2, but not paqr7 and paqr8, were highly abundant in various neuroendocrine 
nuclei, and most notably in the AVPV (Intlekofer and Petersen, 2011a). Although 
Pgrmc1 has been widely studied in granulosa and cancer cells, its function is quite 
elusive in the POA, thus making it a vital candidate to study rapid P4 effects in the 
AVPV.   
 
Pgrmc1’s structure allows it to perform a variety of functions.  It contains a cytochrome 
b5-like heme binding domain that activates P450 proteins involved in steroidogenesis 
(Hughes et al., 2007).  Pgrmc1 is also known to form complexes with various proteins, 
such as steroid regulatory element-binding protein cleavage activating protein (Scap), 
insulin-induced gene (Insig1), and epidermal growth factor receptor (Egfr) (Ahmed et al., 
2010a, 2010b).  While Pgrmc2, neudesin, and serpine1 mRNA binding protein 1 (Serbp1) 
do not display P4-binding activity, they can bind Pgrmc1 and may affect its affinity for 
P4. SH2 and SH3 target motifs are also important components of Pgrmc1 that regulate 
tyrosine kinases and activate signaling cascades, such as those involving protein kinase G 
and mitogen-activated protein kinase/extracellular signal-regulated kinase 1 and 2 
(Mapk/Erk) (Peluso et al., 2006; Cahill, 2007).  Such activation of signaling cascades 
may be the key to which P4 exerts its fast effects.  A recent study revealed that P4 rapidly 
inhibits GnRH neurons via Pgrmc1 activation of protein kinase G (Bashour and Wray, 
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2012).  Pgrmc1’s versatility is also underscored by the fact that it has been localized to 
the cell membrane, cytoplasm, endoplasmic reticulum, mitochondria, and nucleus (Cahill, 
2007).   
 
1.4 Janus kinase/Signal transducer and activator of transcription (Jak/Stat): targets 
of Pgrmc1 
Interested in Pgrmc1’s role in the AVPV and GnRH release, Intlekofer and Petersen 
performed a series of microarray analyses using N42 mouse embryonic hypothalamic 
neurons with and without Pgrmc1 silencing to identify its downstream targets.  Four out 
of the five pathways regulated by Pgrmc1 knockdown in these experiments involved 
signal transducer and activator of transcription (Stat) (Intlekofer, unpublished).  ChIP-Seq 
analyses in granulosa cells supported these findings and also identified Pgrmc1 as a 
regulator of the Janus kinase (Jak)/Stat family (Peluso, personal communication).   
 
The Jak/Stat pathway is a conserved intracellular signaling mechanism found in most 
eukaryotes.  Hormone or cytokine activation of receptors initiate Jak phosphorylation of 
Stats, which dimerize and translocate to the nucleus to regulate transcription (Linnekin et 
al., 1997).  While Jak/Stat proteins are ordinarily expressed at lower levels in the brain 
than other tissues, they are known to have roles in neuronal development (Garza et al., 
2008), hormone release (Wu et al., 2011), inflammation (Yu et al., 2009), and 
tumorogenesis (Hussain et al., 2007).  Energy homeostasis regulated by the hypothalamus 
also relies heavily on leptin-mediated Jak/Stat signaling (Gorska et al., 2010).   In non-
5 
 
neural tissues, including breast cancer cells, P4 activates Jak, recruiting Stat5a to induce 
Pgr expression (Subtil-Rodriguez et al., 2008). 
 
1.5 Rationale and Objectives 
The evidence described above supports the hypothesis of the current study: P4 regulates 
Jak/Stat signaling in the AVPV through Pgrmc1.  This novel idea linking Pgrmc1 and 
Jak/Stat signaling builds on previous data illustrating that these molecules are crucial for 
similar physiological and cellular processes.  In non-neural tissues, both Pgrmc1 and 
Jak/Stat are involved in cholesterol metabolism and steroid hormone synthesis, 
inflammatory response, and tumorigenesis involving EGFR signaling. (Leung et al., 
2003; Proietti et al., 2005; Ahmed et al., 2010a; Lange et al., 1999).  Both molecules are 
also important players in reproduction and GnRH release.  Low levels of pgrmc1 have 
been associated with premature ovarian failure and polycystic ovary syndrome (Schuster 
et al., 2010), while neuronal Jak2 conditional knockout mice have reduced GnRH mRNA 
levels and experience decreased fertility (Wu et al., 2011).  Investigating Pgrmc1 control 
of Jak/Stat molecules and intracellular signaling mechanisms in the in the AVPV is 
important for elucidating their roles in these processes. 
 
In these studies, I used in vitro and in vivo models to investigate regulation of Jak/Stat 
signaling through non-classical P4 receptors.  The N42 mouse embryonic hypothalamic 
cell line was used to perform siRNA experiments with Pgrmc1 and Paqrs and P4 
treatments to assess their downstream effects on Jak/Stat mRNA.  N42 cells model the 
AVPV because they contain abundant ERα, ERβ, Pgrmc1, Pgrmc2, and Serbp1.  In 
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addition they have no detectable Pgr, making them suitable for studying P4 effects on 
Pgrmc1.  Jak/Stat and Paqr mRNAs were also measured in AVPV microdissections from 
Pgrmc1 and Pgrmc2 double conditional knockout (DCKO) mice. 
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CHAPTER 2 
MATERIALS AND METHODS 
 
2.1 Study 1:  Pgrmc1 regulation of Jak/Stat mRNA in the absence and presence of 
P4  
To determine whether P4 and Pgrmc1 regulate Jak/Stat synthesis, Pgrmc1 silencing and 
regulation by P4 was first verified in N42 cells via qPCR and western blot.  Jak1, Jak2, 
Stat3, Stat5a, Stat5b, and Stat6 mRNA levels were measured in these cells lacking 
Pgrmc1 and treated with and without P4.   
 
siRNA transfection and P4 treatments 
N42 cells were seeded at a density of 1.2 x 105 per reaction in Dulbecco’s Modification 
of Eagle’s Medium (DMEM; Thermo Fisher Scientific, Rockford, IL) supplemented with 
20% fetal bovine serum (FBS; Thermo Fisher Scientific) and 1 % penicillin streptomycin 
glutamine (PSG).  They were transfected immediately with AllStars Negative Control 
siRNA or Mm_Pgrmc1_1 Flexitube siRNA; (Qiagen, Valencia, CA) to a final 
concentration of 20 nM with HiPerfect Transfection Reagent (Qiagen) according to the 
manufacturer’s protocol.  Cells were incubated at 37°C in 5% CO2.  Forty-eight hours 
later, media was removed and cells were washed with phosphate buffer saline (PBS) and 
replaced with DMEM containing either ethanol vehicle control or 10 nM P4.  Cells were 
harvested in Trizol 3 hours later and stored at -80°C. 
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RNA isolation and quantitative polymerase chain reaction (QPCR) 
RNA was isolated in Trizol (Invitrogen) according to the manufacturer’s protocol and 
reverse transcribed using the M-MLV Reverse Transcription kit (Promega, Madison, 
WI).  For quantitative polymerase chain reaction (QPCR), cDNA was diluted 1:10 in 
nuclease-free water and combined with FastStart Universal SYBR Green (ROX) mix 
(Roche Applied Science, Indianapolis, IN) with the appropriate primer.  Primers for 
Pgrmc1, Jak1, Jak2, Stat5a, Stat5b, and Stat6 (Integrated DNA Technologies, Coralville, 
IA) are listed in Table 1.  Primers for Gapdh and Stat3 were pre-designed from Qiagen 
(Valencia, CA).  Reactions were completed using the Stratagene MX3005P thermocycler 
(Agilent Technologies, Wilmington, DE) with the following settings:  95°C for 10 
minutes and 40 cycles of 95°C for 15 seconds, 60°C for 30 seconds, and 72°C for 30 
seconds.  Reactions using Qiagen prevalidated primers were set to 95°C for 10 minutes 
and 40 cycles of 95°C for 15 seconds and 60°C for 1 minute.  Threshold cycle (Ct) 
numbers were obtained with MxPro™ QPCR analysis software (Agilent Technologies) 
and the delta delta Ct method of analysis (Livak and Schmittgen, 2001) was used to 
compare treatment effects on target genes.  Target genes were normalized to Gapdh 
housekeeping gene.  All results were analyzed with GraphPad Prism Software (GraphPad 
Software, Inc., San Diego, CA) using a one-way ANOVA with Newman-Keuls 
correction for post hoc analysis when an interaction of main effects was found. 
 
Western Blotting 
N42 cells were lysed in radioimmunoprecipitation assay (RIPA) buffer (Thermo Fisher 
Scientific, Rockford, IL) with 1% protease and phosphatase inhibitor cocktail (Thermo 
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Fisher Scientific) according to the manufacturer’s protocol.  Protein concentrations were 
obtained using the Pierce biocinchoninic acid (BCA) assay (Thermo Fisher Scientfic).  
Ten micrograms of sample protein were loaded onto a 4-15% Tris-HCL SDS-PAGE 
precast gel (Bio-Rad Laboratories, Inc., Hercules, CA) and run at 150V for one hour.  
Protein was electrophoretically transferred to an Immobilon-P PVDF membrane (EMD 
Millipore, Billerica, MA) at 46V for 90 minutes.  The membrane was blocked overnight 
in Tris buffered saline 0.05% Tween-20 (TBST) with 5% non-fat dry milk  at 4°C and 
then probed with anti-Pgrmc1 antibody (1:1000; Abcam, Cambridge, MA) or anti-β-actin 
antibody (1:5000; Abcam) in TBST with 5% milk for 1 hour at room temperature.  After 
washing the membrane three times for 10 minutes in TBST, the secondary antibody 
solution, containing anti-rabbit horseradish peroxidase conjugated antibody (1:15,000; 
Abcam) in TBST with 5% milk, was applied for 1 hour at room temperature.  The 
membrane was washed three times for 10 minutes and chemiluminescence was 
performed using the Clarity ECL Western Blotting Substrate kit (Bio-Rad Laboratories, 
Inc.) and ImageQuant Las 4000 mini (GE Healthcare, Waukesha, WI). 
 
2.2 Study 2:  Pgrmc1 and Pgrmc2 regulation of jak/stat in the AVPV 
To determine whether Pgrmc1 regulated Jak/Stat mRNA levels in vivo, expression of 
jak1, jak2, stat3, stat5a, stat5b, and stat6 was measured in microdissections of the AVPV 
from control and Pgrmc1 and Pgrmc2 DCKO mice.   
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Tissue Preparation  
Brains were removed from Pgrmc1 and Pgrmc2 DCKO and control female mouse heads 
obtained from the John J. Peluso laboratory (UConn Health Center, Farmington, CT).  
Coronal cryosections were obtained at 12μm using the Microm HM 525 Cryostat 
(Thermo Fisher Scientific) at -12°C.  Once the AVPV was reached, as was determined by 
the appearance of the optic recess and anterior commissures, a 300μm coronal section 
was collected and the AVPV was immediately excised using a 2mm circular Harris Uni-
Core™ stainless steel tissue micropunch needle (Ted Pella Inc., Redding, CA).  
Micropunches were transferred to a 1.5 mL microcentrifuge tube on dry ice.  Two AVPV 
samples were pooled for total RNA isolation using Trizol (Invitrogen, Carlsbad, CA) and 
the Qiagen RNeasy Lipid Kit (Qiagen, Valencia, CA).  RNA was reversed transcribed 
with the Quantitect Reverse Transcription kit (Qiagen) according to the manufacturer’s 
protocol and validated on the QPCR as described above.  Statistical analysis was 
performed on each gene independently using student two-tailed t-tests. 
 
2.3 Study 3:  Effects of Paqr7 and Paqr8 on synthesis of Jak1, Jak2 and non-
classical P4 receptors 
To determine whether other P4 mediators regulate Jak synthesis, Paqr7 and Paqr8 siRNA 
experiments with and without P4 were carried out in N42 cells as in Study 1.  Knockdown 
experiments used Qiagen Flexitube siRNAs for Paqr7 (Mm_MGI:1919154_1) and Paqr8 
(Mm_1700019B16Rik_1).  Pre-validated primers for Paqr7 and Paqr8 mRNAs were 
obtained from Qiagen (Valencia, CA).  Levels of Paqr7, Paqr8, Pgrmc1, Jak1, and Jak2 
mRNAs were measured using QPCR as in Study 1.   
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2.4 Study 4:  Pgrmc1 regulation of Paqr7 and Paqr8. 
To determine whether Pgrmc1 regulates Paqr7 and Paqr8 mRNAs in a P4-dependent or -
independent manner, Paqr7 and Paqr8 mRNA levels were measured in N42 cells 
transfected with scramble or Pgrmc1 siRNA in the presence or absence of P4 as in Study 
1.  Paqr7 and Paqr8 mRNAs were also assessed in the DCKO animals as in Study 2.   
 
2.5 Study 5:  Pgrmc1-dependent targets linked to Jak/Stat signaling  
I used the Mouse JAK/STAT RT2 Profiler PCR Array (Qiagen, Valencia, CA) and 
siRNA technology to identify targets of Pgrmc1 linked to Jak/Stat signaling in N42 cells.  
The PCR array reports on 84 genes that are closely related to Jak/Stat-mediated signaling. 
Cells were transfected with and without Pgrmc1 siRNA as described above.  RNA 
isolation was performed in Trizol (Invitrogen, Carlsbad, CA) according to the 
manufacturer’s protocol.  The RT2 First Strand Kit (Qiagen) was used to reverse 
transcribe 1μg RNA.  Synthesized cDNA was prepared with RT2 SYBR Green 
Mastermix (Qiagen) according to the manufacturer’s protocol and loaded onto the 
Jak/Stat PCR array plate for QPCR analysis.  Cycling conditions were as follows:  95°C 
for 10 minutes and 40 cycles of 95°C for 15 seconds and 60°C for 1 minute.   Ct values 
were exported and loaded into SABioscicences Web-based PCR Array Data Analysis 
Software (Qiagen) for analysis.  I then used QPCR with prevalidated primers from 
Qiagen to verify these findings in N42 cells treated as described in Study 1. 
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Finally, I tested whether the identified genes were affected by knockdown of Pgrmc1 and 
Pgrmc2 in the AVPV of DCKO animals as in Study 2.   
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Table 1.  Primers for QPCR validation 
 
 
 
 
 
 
 
Gene 5’ – 3’ Sequence Accession 
Number 
Mouse Pgrmc1 Forward CCTCTGCATCTTCCTGCTCTA NM_016783 
Reverse CGAGCTGTCTCGTCTTTTGG 
Mouse Jak 1 Forward CAGAAAAGCAGCCAACAACA NM_146145 
Reverse CTTGACAGCTACCTGCTCCC 
Mouse Jak 2 Forward TGTGAACTGTTTTCCCTCCC NM_008413 
Reverse TTCAGCTTGCCCAAGAGAAT 
Mouse Stat5A Forward CCGTGGGATGCTATTGACTT NM_011448 
Reverse TCTGGAGCTGTGTGGCATAG 
Mouse Stat5B Forward CTTGGCTTTCGATCCACTGT NM_001113563 
Reverse GGCAGAACGAGGTTGTGAAC 
Mouse Stat6 Forward GGCTTTCCGGAGTCACTATAA NM_009284 
Reverse GTCCCTTTCCACAGTCATCTT 
Mouse Nr4a1 
 
Forward TTCCCACCACCAGCCACCCA NM_010444 
Reverse CTCGCTGCCACCTGAAGCCC 
14 
 
CHAPTER 3 
RESULTS 
 
3.1 Study 1 
P4 does not regulate Pgrmc1 mRNA levels  
In order to test P4 and Pgrmc1 downstream effects, Pgrmc1 silencing was first verified in 
N42 cells along with Pgrmc1 response to P4 treatments.  Transfection with Pgrmc1 
siRNA and ethanol vehicle control (veh) reduced Pgrmc1 mRNA levels to 36.7% of 
controls and also significantly reduced protein levels (Fig.1 A and B).  Subsequent P4 
treatments did not affect Pgrmc1 mRNA levels in scramble or Pgrmc1 siRNA transfected 
cells (Fig.1 B).   
 
Pgrmc1 control of Jak1 and Jak2 synthesis is both P4 dependent and independent 
To determine whether Jak/Stat synthesis is affected by Pgrmc1 and P4, Jak1, Jak2, Stat3, 
Stat5a, Stat5b, and Stat6 mRNA levels were validated in N42 cells transfected with either 
scramble control or Pgrmc1 siRNA and treated with either veh or P4.  Jak1 and Jak2 
mRNA levels significantly increased with Pgrmc1 silencing alone (Fig.2 A and B).  P4 
treatments in scramble-transfected cells increased Jak1 and Jak2 synthesis.  When treated 
with Pgrmc1 siRNA and P4 together, Jak1 mRNA levels significantly decreased 
compared to that of both scramble-vehicle and scramble-P4 controls (Fig.2 A).  Jak2 
mRNA levels also decreased significantly compared to that of scramble-P4 (Fig.2 B).  
Stat3, Stat5a, and Stat6 synthesis did not appear to be significantly regulated by the 
absence of Pgrmc1 or presence of P4 (Fig.2 C-F).   
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3.2 Study 2 
Jak2 mRNA levels drastically decrease in the absence of Pgrmc1 and Pgrmc2 in the 
AVPV 
To asses Pgrmc1 regulation of Jak/Stat molecules in vivo, mRNA levels of Jak/Stats were 
analyzed in mouse AVPV microdissections from control and Pgrmc1 and Pgrmc2 DCKO 
mice.  Pgrmc1 mRNA levels in DCKO animals were decreased to 24.5% that of the 
controls (Fig.3 A).  Jak1 did not appear to be regulated by Pgrmc1 and Pgrmc2 silencing, 
but Jak2 mRNA levels were almost undetectable in DCKO animals at 1.9% that of 
controls (Fig. 3B).  Stat3, Stat5a, Stat5b, and Stat6 mRNA levels did not appear to be 
significantly regulated by Pgrmc1 and Pgrmc2 knockdown (Fig 3C).  
 
3.3 Study 3  
Absence of Paqr8, but not Paqr7, affects Jak1, and Jak2 synthesis 
Results suggesting that another component may be involved in P4 and Pgrmc1 regulation 
of Jak1 and Jak2 (Fig.2 A and B; Fig.3 B) prompted me to look at Paqr7 and Paqr8 
involvement.  N42 cells were transfected with either scramble control, Paqr7 or Paqr8 
siRNA and treated with either veh or P4 to assess Paqr7 and Paqr8 regulation of Pgrmc1, 
Jak1, and Jak2 (Figs. 4 and 5).  Paqr7 mRNA levels were knocked down to 29.7% that of 
scramble/veh control.  Treatment with P4 in scramble and Paqr7-siRNA transfected cells 
also appeared to downregulate Paqr7 synthesis (Fig.4 A).  Pgrmc1, Jak1, and Jak2 basal 
transcription levels were not affected by the absence of Paqr7 (Fig.4 B-D).   
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Paqr8 mRNA levels were knocked down to 34.7% that of scramble/veh control.  P4 
treatment significantly upregulated Paqr8 synthesis in scramble-transfected cells, but had 
no effect in cells transfected with Paqr8 siRNA (Fig.5 A).  Pgrmc1 mRNA levels were 
not affected by the absence of Paqr8 (Fig.5 B).  Paqr8 silencing alone did not cause any 
significant changes in Jak1 and Jak2 basal level transcription, but in the presence of P4, it 
abrogated Jak1 and Jak2 upregulation by P4 (Fig.5 C and D).   
 
3.4 Study 4 
Pgrmc1 regulates Paqr7 and Paqr8 synthesis 
P4 and Pgrmc1 regulation of Paqr7 and Paqr8 was first assessed in N42 cells transfected 
with either scramble or Pgrmc1 siRNA and treated with either veh or P4.  Pgrmc1 
silencing alone did not affect Paqr7 mRNA levels, but P4-treated cells showed slight 
downregulation in basal levels of Paqr7 (Fig.6 A).  Paqr8 mRNA levels increased 
significantly with Pgrmc1 silencing, suggesting a suppressive role of Pgrmc1 on Paqr8 
synthesis (Fig.6 B).  Paqr8 transcript levels were further upregulated with P4 treatments 
alone, and significantly decreased when P4 was administered in the absence of Pgrmc1; 
hence, Pgrmc1 was necessary for P4 upregulation of Paqr8.  Examination of Paqr7 and 
Paqr8 in vivo showed that Paqr7 mRNA levels in the AVPV significantly increased in the 
absence of Pgrmc1 and Pgrmc2 (Fig.6 C).  Paqr8 mRNA levels appeared to increase in 
the DCKO animals, but not significantly; therefore, I performed a power analysis and 
determined that an n of 8 would be necessary to detect differences based on the 
variability within treatments.   
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3.5 Study 5 
Identification of Pgrmc1 and Jak/Stat downstream gene targets 
The Mouse JAK/STAT Signaling Pathway RT2 Profiler PCR Array (Qiagen) was used to 
find putative gene targets regulated by Pgrmc1 and Jak/Stat.  In the absence of Pgrmc1, 
four genes were identified as significantly upregulated and eight genes downregulated by 
at least 1.5 fold (Table 2).  Genes picked for further analysis were those known from the 
literature to be involved in P4 signaling or present in neurons.  They included nuclear 
factor of kappa light polypeptide gene enhancer in B-cells I (Nfkb1), protein tyrosine 
phosphatase, non-receptor type I (Ptpn1), SMAD family member 5 (Smad5), and Stat2.   
 
Nfkb1 and Smad5 are potential targets of Pgrmc1 and Jak/Stat signaling 
To determine whether Pgrmc1 silencing and P4 affect synthesis of the PCR array-
identified downstream targets, mRNA levels of Nfkb1, Ptpn1, Smad5, and Stat2 were 
validated on the QPCR from N42 cells transfected with scramble or Pgrmc1 siRNA and 
treated with either veh or P4 (Fig.7).  Nuclear receptor subfamily 4, group A, member 1 
(Nr4a1), a gene detected on the same microarray as the Stats for regulation by Pgrmc1 
(Intlekofer, unpublished), was also evaluated (Fig.7 B).  Of the genes investigated, only 
Nfkb1 mRNA decreased as a result of Pgrmc1 silencing, but no effect was seen in the 
presence of P4 (Fig.7 A).  Smad5 mRNA levels significantly decreased as a result of 
Pgrmc1 siRNA transfection and P4 treatment, but no effect was seen with Pgrmc1 
silencing or P4 treatment alone (Fig.7 D).  This may suggest a Pgrmc1-independent effect 
of P4, but further verification must be performed.  Nr4a1, Ptpn1, and Stat2 were not 
significantly regulated by either Pgrmc1 silencing or P4 treatment (Fig.7 B, C and E).  
18 
 
Transcript levels of the target genes were also analyzed in the AVPV of control and 
Pgrmc1 and Pgrmc2 DCKO mice.  None of the genes were significantly regulated in 
DCKO animals, but this may be due to insufficient power of the analysis (Fig.7 F).  
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Figure 1. Pgrmc1 siRNA experiments and P4 treatments 
Pgrmc1 silencing was detected by western blot in N42 cells transfected with either 
scramble control or Pgrmc1 siRNA and compared with β-actin (A).  Pgrmc1 mRNA 
levels were validated on the QPCR from N42 cells transfected with either scramble 
control or Pgrmc1 siRNA for 48 hours followed by a 3-hour treatment with either ethanol 
vehicle control (Veh) or 10 nM P4 (B).  Treatment with Pgrmc1 siRNA/Veh produced a 
decrease in Pgrmc1 mRNA to 36.7% that of Scramble/Veh (B).  Results were analyzed 
using a one-way ANOVA with Newman-Keuls correction; bars=means±SEM. 
aSignificantly different from Scramble/Veh; bsignificantly different from Pgrmc1 
siRNA/Veh; csignificantly different from Scramble/P4. 
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Figure 2.  Effects of Pgrmc1 siRNA and P4 on Jak/Stat gene expression 
Jak/Stat mRNA levels were validated on the QPCR in N42 cells transfected with either 
scramble control or Pgrmc1 siRNA for 48 hours followed by a 3-hour treatment with 
either ethanol vehicle control (Veh) or 10 nM P4 (A-F).  Results were analyzed using a 
one-way ANOVA with Newman-Keuls correction; bars=means±SEM.  aSignificantly 
different from Scramble/Veh; bsignificantly different from Pgrmc1 siRNA/Veh; 
csignificantly different from Scramble/P4. 
 
 
 
C 
F 
A B 
D 
E 
21 
 
 
 
 
 
 
AVPV Pgrmc1
0
100
200
300
Control
Pgrmc1/2 DCKO
*Pg
rm
c
1
 m
R
N
A
 L
e
v
e
ls
(%
 C
o
n
tr
o
l)
AVPV Jaks
Ja
k1
Ja
k2
0
100
200
300
Control
Pgrmc1/2 DCKO
*
J
a
k
 m
R
N
A
 L
e
v
e
ls
(%
 C
o
n
tr
o
l)
AVPV Stats
S
ta
t3
S
ta
t5
a
S
ta
t5
b
S
ta
t6
0
100
200
300
Control
Pgrmc1/2 DCKO
S
ta
t 
m
R
N
A
 L
e
v
e
ls
(%
 C
o
n
tr
o
l)
 
 
Figure 3.  Gene regulation in the AVPV of Pgrmc1 and Pgrmc2 DCKO mice 
Pgrmc1 and Jak/Stat mRNA levels were validated on the QPCR from AVPV 
microdissections of control and Pgrmc1 and 2 DCKO animals (n=5, A-D).  Jak2 mRNA 
was knocked down to 1.9% in DCKO animals as compared to controls (B).  Each gene 
was analyzed independently with a student t-test; bars=means±SEM. *Significantly 
different from control; p < 0.05. 
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Figure 4.  Paqr7 siRNA experiments with P4 treatments 
Paqr7, Pgrmc1, Jak1, and Jak2 mRNA levels were analyzed via QPCR in N42 cells 
transfected with either scramble control or Paqr7 siRNA for 48 hours followed by a 3-
hour treatment with either ethanol vehicle control (Veh) or 10 nM P4 (A-E).  Paqr7 
mRNA levels were knocked down to 29.7% that of the Scramble/Veh control (A).  
Results were analyzed using a one-way ANOVA with Newman-Keuls correction; 
bars=means±SEM. aSignificantly different from Scramble/Veh; bsignificantly different 
from Pgrmc1 siRNA/Veh; csignificantly different from Scramble/P4. 
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Figure 5.  Paqr8 siRNA and P4 regulation of Jak1 and Jak2 
mRNA levels for Paqr8, Pgrmc1, Jak1, and Jak2 were validated on the QPCR from N42 
cells transfected with either scramble control or Paqr8 siRNA for 48 hours followed by a 
3-hour treatment with either ethanol vehicle control (Veh) or 10 nM P4 (A-E).  Paqr8 
mRNA levels were knocked down to 34.7% that of scramble vehicle control (A).  Results 
were analyzed using a one-way ANOVA with Newman-Keuls correction; 
bars=means±SEM. aSignificantly different from Scramble/Veh; bsignificantly different 
from Pgrmc1 siRNA/Veh; csignificantly different from Scramble/P4. 
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Figure 6.  Pgrmc1 regulation of Paqr7 and Paqr8 
Paqr7 and Paqr8 mRNA levels were analyzed in N42 cells transfected with either 
scramble control or Pgrmc1 siRNA for 48 hours followed by a 3-hour treatment with 
either ethanol vehicle control (Veh) or 10 nM P4 (A and B).  Paqr7 and Paqr8 mRNA 
levels were analyzed in the AVPV of control and Pgrmc1/2 DCKO mice (C).  Results in 
A and B were analyzed using a one-way ANOVA with Newman-Keuls correction and a 
student t-test was used to analyze each gene separately in C; bars=means±SEM. 
aSignificantly different from Scramble/Veh; bsignificantly different from Pgrmc1 
siRNA/Veh; csignificantly different from Scramble/P4. *Significantly different from 
control; p < 0.05. 
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Table 2.  Genes regulated by Pgrmc1 and Jak/Stat from PCR array  
Symbol Gene Name Fold Change 
Ptpn1 Protein tyrosine phosphatase, non-receptor type I 7.3279 
Fcgr1 Fc receptor, IgG, high affinity I 2.0187 
Socs2 Suppressor of cytokine signaling II 1.6975 
Nfkb1 Nuclear factor of kappa light polypeptide gene 
enhancer in B cells I, p105 
1.5088 
Il4ra Interleukin 4 receptor, alpha -2.023 
Csf2rb2 Colony stimulating factor 2 receptor, beta, low 
affinity 
-1.995 
Tyk2 Tyrosine kinase 2 -1.8875 
Stam Signal transducing adaptor molecule -1.836 
Smad5 SMAD family member 5 -1.737 
Stat2 Signal transducer and activator of transcription 2 -1.713 
Saa3 Serum amyloid A 3 -1.587 
Gusb Glucuronidase, beta -1.501 
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Figure 7.  QPCR validation of Pgrmc1 and Jak/Stat downstream target genes  
mRNA levels of selected genes from the PCR array data set and microarray data 
(Intlekofer, unpublished) were assessed in N42 cells treated with either scramble control 
or Pgrmc1 siRNA and ethanol vehicle control (Veh) or 10 nM P4 (A-E).  mRNA levels 
of the target genes were assessed in AVPV microdissections of control and Pgrmc1 and 
Pgrmc2 DCKO mice (F).  Results in A-E were analyzed using a one-way ANOVA with 
Newman-Keuls correction and a student t-test was used to analyze each gene separately 
in F; bars=means±SEM. aSignificantly different from Scramble/Veh; bsignificantly 
different from Pgrmc1 siRNA/Veh; csignificantly different from Scramble/P4. 
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CHAPTER 4 
DISCUSSION 
 
My in vitro findings are the first to show that P4 increases synthesis of Jak1 and Jak2 
through a mechanism that requires both Pgrmc1 and Paqr8.  In the absence of P4, Pgrmc1 
alone suppresses Jak1 and Jak2 mRNA levels.  My in vivo findings suggest that Paqr8 
and/or Pgrmc2 act in concert with Pgrmc1 to regulate Jak1 and Jak2 synthesis.   
Together, these results indicate that P4 in hypothalamic neural cells regulates Jak1 and 
Jak2 signaling by a complex interaction among Pgrmc1, Pgrmc2 and Paqr8.  Further 
studies are necessary to determine the downstream targets of Pgrmc1 and Jak/Stat, but 
Nfkb1 is a promising candidate. 
 
P4 upregulation of Jak1 and Jak2 mRNA was an important finding because many studies 
have only shown P4 to regulate Jak/Stat phosphorylation (Proietti et al., 2005; Sagare-
Patil and Modi, 2013).  However, steroid hormone regulation of Jak synthesis is not 
completely surprising based on a previous finding in breast cancer cells that demonstrated 
E2 upregulation of Jak2 mRNA (Gupta et al., 2012).  Thus, P4 regulates both Jak/Stat 
signaling and its synthesis. 
 
The coordinated regulation of jak1 and jak2 by P4 through Pgrmc1 and Paqr8 supports 
the newly emerging idea that P4 wields its rapid effects through Pgrmc1 and Paqr 
interactions.  Work from the Thomas lab showed that Pgrmc1 acts as an adaptor for 
Paqr7 and forms complexes at the plasma membrane, resulting in increased P4 binding 
(Thomas et al., 2014).  Overlapping results from the Peluso lab showed that Pgrmc1, 
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Pgrmc2, and Paqr7 interact in the cytoplasm and all three components are necessary to 
block P4 anti-mitotic effects (Sueldo et al., 2015).  In the Thomas and Peluso studies, 
Paqr8 was not studied because it is in low abundance in ovarian and breast cancer cells.  
In contrast, my findings showed that Paqr8, rather than Paqr7, mediated the effect of P4 
and Pgrmc1 on Jak1 and Jak2 synthesis in neural cells.  This finding supports previous 
data indicating that Paqr8 is more abundant and responsive to P4 than Paqr7 in the 
hypothalamus (Zuloaga et al., 2012; Intlekofer and Petersen, 2011a).     
 
My in vitro findings indicate that Pgrmc1 constitutively represses both jak1 and jak2 
expression.  Although the mechanism is not yet clear, previous evidence has shown that 
Pgrmc1 can activate several signaling pathways.  In GnRH neurons, P4 binds Pgrmc1 to 
activate protein kinase G and rapidly inhibit GnRH secretion (Bashour and Wray, 2012).  
In pancreatic β cells, Pgrmc1 increases adenyl cyclase/EPAC and regulates the EGF 
receptor-PI3K signal transduction pathway (Zhang et al., 2014).   Pgrmc1 may also 
operate like a transcription factor, as it has been shown in spontaneously immortalized rat 
granulosa cells (SIGCs; Peluso et al., 2012).   
 
The apparent discrepancy between my in vitro and in vivo findings where Jak2 mRNAs 
increased in N42 cells lacking Pgrmc1, but decreased in animals lacking Pgrmc1 and 
Pgrmc2 suggest that Pgrmc2 and Paqr8 may also play roles in P4 upregulation of jak1 and 
jak2 gene expression.  This idea that Pgrmc1, Paqr8, and Pgrmc2 interact together to 
regulate gene expression correlates with the findings in ovarian cells where Pgrmc1, 
Paqr7, and Pgrmc2 form complexes with each other in the cytoplasm (Sueldo et al., 
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2015).  On the other hand, Pgrmc1, Pgrmc2 and Paqr8 could work independently of each 
other to regulate the same molecules.  For example, Paqr8 alone is known to activate G 
proteins and Jak/Stats are known downstream targets of G-protein coupled receptors (Zhu 
et al., 2003; Pelletier et al., 2003).   
 
Identification of Nfkb1 as a downstream target of Pgrmc1 and Jak/Stat is an interesting 
finding because Nfkb1 is anti-apoptotic in the developing female AVPV (Petersen et al., 
2012).   Nfkb1 is the p105 precursor to the p50 transcription factor in canonical Nfkb 
signaling (Sun, 2011).  Although not much is known about Nfkb1 signaling in the 
hypothalamus, it does have roles in learning and memory (Lehmann et al., 2010) and 
synaptic plasticity (Li et al., 2015) in the central nervous system.  These are intriguing 
findings because both P4 and Pgrmc1 regulate the same functions (Petersen et al., 2013).  
Although Pgrmc1 and Nfkb1 have never been linked before, both inhibit inflammation 
(Rolova et al., 2014) and regulate MAPK (Yang et al., 2011).  Thus, manipulation of 
Pgrmc1 signaling may broaden the clinical approaches to treating brain injuries and 
neuroinflammation.   
 
In conclusion, our results demonstrate that Pgrmc1 and Paqr8 are significant mediators of 
P4-dependent and -independent regulation of Jak1 and Jak2 synthesis in neuroendocrine 
cells and nuclei.  Further studies are needed to determine the mechanisms through which 
Pgrmc1 and Paqr8 interact to regulate Jak1 and Jak2 mRNA levels.  Similarly, the role of 
Pgrmc2 in controlling Pgrmc1 and Paqr8 interactions remains to be determined.  
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Unveiling the mechanisms through which P4 regulates Jak/Stat signaling will increase our 
understanding of how P4 rapidly amplifies the LH surge.    
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